When Lou Schmukler joined Bristol-Myers Squibb (BMS) in 2011, it was analogous to jumping onto a moving train. The company’s biopharma transformation was barreling ahead at full steam. More change was coming, and the company’s manufacturing operations would need to move fast to keep up.
The heads of the East and West Coast Innovation Centers for Bayer Healthcare discuss their parallel missions, therapeutic areas of focus, and dealmaking models.
When Celgene began pursuing an aggressive acquisition strategy, David Stirling, Ph.D., a cofounder, decided to leave and eventually start his own company, BioTheryX.
Don DeGolyer talks about the process he took to go from working at a Big Pharma like Sandoz to founding and running his own small specialty pharma company.
How Katherine High, M.D., cofounder, president, and head of R&D at Spark Therapeutics, helped reinvigorate the life sciences industry’s interest in gene therapy.
Women in leadership roles in the biopharma industry say it is imperative that the industry’s gender gap problem be addressed — by both men and women. Because, if the current trend of women leaving the industry continues, this problem will become a worker-shortage problem and reduce innovation that is vital for industry growth.
Six months after Amgen acquired Onyx Pharmaceuticals, Tony Coles, M.D. was pondering his next move. The former Onyx CEO wasn’t planning to lead another pharma company so soon … but then he got a phone call.
Ameet Nathwani, M.D., EVP of medical function at Sanofi, gives the inside scoop on what’s required when it comes to preparing a Big Pharma to be digital-health ready.
A summary from the BIO conference panel “Don’t Be Foreign To Foreign Affairs — How To Broker Biopharma Strategic Alliances And Partnerships Between International Stakeholders”
Alexis Howerton is a first-time pharma CEO who saw potential in an older drug class that had failed in its targeted indications. She then jumped feet first into obtaining the ideal candidate compound and starting a company to develop it.
“We had to decide whether to spend a lot of money to bring on a sales force and marketing team, and expand manufacturing to meet demand, or take our resources and refocus them on these rare disorders.”
Tom Wiggans, founder, chairman, and CEO of Dermira, provides an overview of the dermatology market, the impetus for founding Dermira, and transparently shares his experience regarding his company’s Phase 3 clinical trial failures.
Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses how the company is preparing to launch a new CNS product likely to change the paradigm for how postpartum depression is treated.
From founding the company to funding it, the CEO of Aurinia Pharmaceuticals explains the genesis of the company and why he left retirement to return to guide the company.
Novartis Oncology CEO, Liz Barrett, on career advancement and family, a common challenge for women in the workplace.
Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, provides a preview as to his approach to transformation the company’s product development and manufacturing operations, along with insight into the world of biopharmaceutical outsourcing.
Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, explains some of the nuances between small and large molecule drug manufacturing.
Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.
Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
